Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Mankind corporate presentation

Mankind Pharma

Ähnliche Hörbücher

Kostenlos mit einer 30-tägigen Testversion von Scribd

Alle anzeigen
  • Loggen Sie sich ein, um Kommentare anzuzeigen.

  • Gehören Sie zu den Ersten, denen das gefällt!

Mankind corporate presentation

  1. 1. 236, Okhla Industrial Estate- III, New Delhi- 110020 INDIA MARCH 2015
  2. 2. Branded generics market with Doctors playing a significant role Source: McKinsey & Co Physician Pharmacy Payer Key Influencer Product brand (e.g. Storvas) TypeofBranding Company brand (e.g. Ranbaxy Atorvastatin) Unbranded (e.g. Atorvastatin) INDIA Poland China Russia Mexico Brazil Italy Spain France Germany UK USA “BRANDED GENERICS” “GENERIC GENERICS”
  3. 3. Source: AIOCD Mar ’14, McKinsey & Co. 30862 75757 189393 - 50,000 1,00,000 1,50,000 2,00,000 Mar '07 Mar '14 Mar '20 (In Crs.) Large & growing addressable domestic market…
  4. 4. Source: IMS 2012, United Nations Department of Economic and Social Affairs $1,019 $558 $342 $147 $49 $11 $- $400 $800 $1,200 US Germany UK Brazil China India Pharmaceutical expenditure per capita in 2012 ($) Low penetration in India presents a huge potential going forward
  5. 5. Source: AIOCD MAT August '14 MAT November '06 Rank Market Share Company Rank Market Share Comment 1 6.3% Abbott 13 2.1% Acquisition (Piramal) 2 5.5% Sun Pharma 6 3.2% Organic, +2.3% share 3 4.9% Cipla 3 5.1% - 4 4.4% Zydus 5 3.5% - 5 3.6% Ranbaxy 2 5.1% - 6 3.6% Mankind 16 1.8% Organic, +1.8% share 7 3.4% Alkem 7 3.0% - 8 3.4% Glaxo 1 5.2% -1.8% share 9 3.4% Lupin 9 2.3% - 10 2.9% Pfizer 8 2.6% - 11 2.8% Macleods 25 1.4% Organic, +1.4% share 12 2.8% Emcure 23 1.5% Roche licensing 13 2.6% Intas 17 1.8% Organic, +0.8% share 14 2.5% Sanofi India 10 2.3% - 15 2.5% Aristo 12 2.3% - Only player to organically breach Top 10 in the past decade
  6. 6. FY 95-96 FY 08-09 FY 09-10 FY 10-11 FY 11-12- FY 12-13 FY 13-14 FY 14-15 SALES $ million 0.8 189 248 317 382 476 560 660 % YOY GR NA 38% 30% 33% 20% 25% 18% 20% MILESTONES Company Founded First Rank in Indiaas per Prescription / Doctor / Month First Rank as per Value Generated from New Launches Launched Pet Mankind Launched Lifestar-2 Pharma Field force reached to 8500 Field force reached to 10,000 Field force reached to 11,000 R & D Set up in Manesar Launched in two states Entered top 10 Domestic ranking Started International Operations in Sri-Lanka International horizons extended to Nepal, Marutius, Kenya, Zambia, Negeria & Bangladesh Global footprints extended to Cambodia & Myanmar Global footprints extended to Philippines Journey so far…
  7. 7. Source: AIOCD, Company reports 15% 15% 18% 16% 13% 16% 12% 7% 52% 32% 38% 30% 32% 20% 23% 17% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 Industry vs Makind YoY Growth Industry Mankind Exceptional growth of 2.2x Industry…
  8. 8. Mankind In Indian Pharma Market TOP 20 CORPORATES (PRESCIPTION/DOCTOR/MONTH) RANK CORPORATES P/D/M 1 MANKIND 93 2 CIPLA 66 3 SUN PHARMA 64 4 GLAXOSMITHKLINE 61 5 MACLEODS PHARMACEU. LTD. 57 6 ALKEM LAB. 51 7 MICRO LABS 50 8 ABBOTT HEALTHCARE 49 9 RANBAXY 49 10 DR.REDDY'S LAB. 49 SOURCE IMS HEALTH OCT.2014 Leading the way in prescription per doctor….Leading the way in prescription per doctor….Leading the way in prescription per doctor….Leading the way in prescription per doctor….
  9. 9. Source: C MARC July-Aug.2014 4.09% 3.36% 3.33% 3.10% 2.7% 0% 9% -2% 5% -3% 8% 2% -4.00% -2.00% 0.00% 2.00% 4.00% 6.00% 8.00% 10.00% Mankind Abbott Cipla Glaxo Sun Total Market Prescription share Growth Prescription Share and Prescription Growth for CY 12 (%) Fastest growth in prescriptions a precursor to future growth
  10. 10. Deep penetration into rural markets, growth potential from Metros Source: IMS Jun 13 30% 31% 19% 20% 18% 27% 24% 30% 0% 10% 20% 30% 40% Metros Class I Class II to VI Rural Revenue split by town-class (LTM June 2013) Industry Mankind
  11. 11. Source: AIOCD 1.9% 3.2% 3.6% 15 9 6 1 5 9 13 170.0% 1.0% 2.0% 3.0% 4.0% FY07 FY10 FY14 Market Share Rank Steady growth in ranking and market share…
  12. 12. Source: Company actuals (In Mn USD) S. No. Brands Type FY 14-15 YoY Growth 1 Nurokind Acute 47 18% 2 Moxikind Acute 32 10% 3 Mahacef Acute 28 0% 4 Zenflox Acute 26 6% 5 Gudcef Acute 26 11% 6 Manforce Condom OTC 19 14% 7 Amlokind Chronic 19 16% 8 Glimestar Chronic 18 20% 9 Unwanted OTC 15 9% 10 Telmikind Chronic 15 43% Total top 10 246 13% As a % of total revenues Brand oriented growth strategy…
  13. 13. Source: AIOCD Mar 14, Company data 8,024 22,727 22,838 53,030 - 20,000 40,000 60,000 80,000 Mar '07 Mar '14 IPM Chronic Acute 42 507480 2,312 - 750 1,500 2,250 3,000 Mar '07 Mar '14 Mankind Chronic Acute Chronic mix % 26% 30% 8% 18%Chronic mix % (In Rs Cr) (In Rs Cr) Strong base in Acute, Fast growth through Chronic…
  14. 14. Anti Diabetic Segment $ 31 million Growth 24% Field Force Promoting – Anti Diabetic Range 2000 Source: ims-Health Sep.2014, Company actuals Strong Presence in Anti Diabetic Segment
  15. 15. RANK Company Name VALUE ($ MILLION) GROWTH (%) 1 ABBOTT 170 10 2 USV 141 5 3 SUN 83 8 4 SANOFI 80 14 5 NORARTIS 55 18 6 MSD 51 25 7 LUPIN 45 19 8 ELI LILY 38 23 9 MANKIND 30 24 10 MICRO 28 -1 11 INTAS 27 11 Source: ims-Health Sep.2014, Company actuals Top Companies of Anti Diabetic Segment
  16. 16. Cardiac Segment $ 52 million Growth 25% Field Force Promoting – Cardic Range 2000 Source: ims-Health Sep.2014, Company actuals Strong Presence in Cardiac Segment
  17. 17. Source: ims-Health Sep.2014, Company actuals RANK Company Name VALUE ($ MILLION) GROWTH (%) 1 SUN 120 11 2 ZYDUS 89 2 3 TORRENT 87 -2 4 LUPIN 85 11 5 CIPLA 75 10 6 USV 73 12 7 GLENMARK 68 17 8 MACLEODS 59 16 9 INTAS 56 1 10 EMCURE 55 4 11 MANKIND 52 25 12 ABBOTT 49 -4 Top Companies of Cardiac Segment
  18. 18. Source: IMS Jun 13 30% 31% 19% 20% 18% 27% 24% 30% 0% 10% 20% 30% 40% Metros Class I Class II to VI Rural Revenue split by town-class (LTM June 2013) Industry Mankind Deep penetration in Rural, Strong potential from Metros…
  19. 19. Manufacturing Capabilities
  20. 20. 14 World Class Manufacturing Units. Most units USFDA & WHO-GMP compliant. Engaged Manufacturing of sterile Injectables , Tablets, Capsules, Liquid Orals, Creams & Ointments Infrastructure – Manufacturing Units
  21. 21. State-of-the-art Research & Development center at Delhi- NCR. Majorly focusing on : • API Development • New Drug Delivery System • Formulation Development • NCE Development Infrastructure – R&D Center
  22. 22. Commercial Presence in Sri-Lanka Bangladesh Kenya Uganda 12121212 Countries Philippines Myanmar Zambia Tanzania Nepal Cambodia Nigeria Mauritius Our Global Presence
  23. 23. ASIAASIAASIAASIA AFRICAAFRICAAFRICAAFRICA Vietnam D R Congo Mozambique Burundi Rwanda Malawi South Sudan Ghana Ethiopia CISCISCISCIS LATAMLATAMLATAMLATAM Kazakhstan Tajikistan Ukraine Brazil Venezuela Ecuador Central America Belarus Uzbekistan Kyrgyzstan Columbia Peru Chile Mexico Shortly Entering
  24. 24. Brand driven strategy with 42 brands in leadership position Pan India coverage through 61 Super distributer & 5000 whole seller. Field force of 11,000 MRs & Managers. Focused Doctor centric approach, cover > 4 Lac Doctors covering Manage a low attrition rate. KEY DIFFERENTIATORS
  25. 25. Won ”Indian Express Pharma Pulse Award” for overall performance in the year 2005. AWARD FOR OVERALL PERFORMANCE AWARD FOR EMERGING COMPANY Won “The Emerging Company of the Year” award at Pharma Excellence Award, 2007. AWARD FOR ENTREPRENEURSHIP Accorded with “The India Business Icon (Pharma)” award by Network 18 for the year 2011 Awarded for being the Sustaining Key GrowthSustaining Key GrowthSustaining Key GrowthSustaining Key Growth Driver for achievingDriver for achievingDriver for achievingDriver for achieving BusinessBusinessBusinessBusiness Excellence by CitiCitiCitiCiti Commercial BankCommercial BankCommercial BankCommercial Bank in 2012 Bestowed as """"EnterpreneurEnterpreneurEnterpreneurEnterpreneur of theof theof theof the Year"Year"Year"Year" by Ernst & YoungErnst & YoungErnst & YoungErnst & Young in 2011in 2011in 2011in 2011 AWARDS & RECOGNITION

×